Are antiangiogenic antibodies universal for solid tumor?;Traitements anti-VEGF: Un emploi universel?

Bulletin du Cancer

Volumn 94, Issue SPECIAL, 2007, Pages

  Ray Coquard, Isabelle ^a   Bachelot, Thomas ^a   Saba, Chadi ^a   Confavreux, Cyrille ^a   Brantus, Jean François ^a   Rustam, Fadi ^a   Ghesquière, Hervé ^a   Sebban, Catherine ^a   Biron, Pierre ^a   Guastalla, Jean Paul ^a   Blay, Jean Yves ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Angiogenesis; Bevacizumab; Breast cancer; Colorectal cancer; Lung cancer; Vascular endothelial growth factor; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; VASCULOTROPIN RECEPTOR;

BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG RESPONSE; HUMAN; LUNG CANCER; META ANALYSIS; REVIEW; SOLID TUMOR; SYSTEMATIC REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; HYPERTENSION; KIDNEY NEOPLASMS; LEUCOVORIN; LUNG NEOPLASMS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 34548649550     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0352     Document Type: Review

References (30)

1. Bikfalvi A. Angiogenese tumorale. Bull Cancer 2003 ; 90 : 449-58.
2. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002 ; 20 : 3906-27.
3. Rosen LS. Clinical experience with angiogenesis signaling inhibitors : focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002 ; 9 (2 Suppl.) : 36-44.
4. Underiner TL, Ruggeri B, Gingrich DE. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 2004 ; 11 : 731-45.
5. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995 ; 146 : 1029-39.
6. Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays 2001 ; 23 : 494-507.
7. Reinmuth N, Liu W, Jung YD, Ahmad SA, Shaheen RM, Fan F, et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 2001 ; 15 : 1239-41.
8. Kitadai Y, Ellis LM, Tucker SL, Greene GF, Bucana CD, Cleary KR, et al. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 1996 ; 149 : 1541-51.
9. Bachelot T, Jouanneau E, Blay JY. Développement clinique d'agents antiangiogéniques. Bull Cancer 2003 ; 90 : 19-23.
10. Iqbal S, Lenz HJ. Angiogenesis inhibitors in the treatment of colorectal cancer. Semin Oncol 2004 ; 31 (6 Suppl. 17) : 10-6.
11. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995 ; 95 : 1789-97.
12. Blay JY, Le Cesne A, Alberti L, Ray-Coquart I. Targeted cancer therapies. Bull Cancer 2005 ; 92 : E13-8.
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 ; 350 : 2335-42.
14. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer : results of a randomized phase II trial. J Clin Oncol 2005 ; 23 : 3697-705.
15. Assenat E, Duffour J, Ychou M. L' irinotécan dans le traitement du cancer colorectal metastatique. Bull Cancer 2006 ; 93 : 507-15.
16. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005 ; 91 : 173-80.
17. Seguta C, Afchain P, de Gramont A, Andre T. Gercor (French Oncology Research Group). Traitement adjuvant du cancer colorectal. Bull Cancer 2006 ; 93 : 683-90.
18. Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, et al. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405 : a phase III trial of chemotherapy and biologies for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer 2005 ; 5 : 292-4.
19. Delmotte P, Martin B, Paesmans M, Berghmans T, Mascaux C, Meert AP, et al. VEGF and survival of patients with lung cancer : a systematic literature review and meta-analysis. Rev Mal Respir 2002 ; 19(5 Pt 1) : 577-84.
20. Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, et al. The role of microvessel density on the survival of patients with lung cancer : a systematic review of the literature with meta-analysis. Br J Cancer 2002 ; 87 : 694-701.
21. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 ; 22 : 2184-91.
22. Belvedere O, Grossi F. Lung Cancer Highlights from ASCO 2005. Oncologist 2006 ; 11 : 39-50.
23. Bay JO, Penault-Llorca F, Ravaud A, Chevreau C, Negrier S, Escudier B. Nouveaux acteurs dans la classification pathologique et les options thérapeutiques dans le carcinome rénal. Bull Cancer 2006 ; 93 : 91-100.
24. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 ; 349 : 427-34.
25. Atiqur RM, Toi M. Anti-angiogenic therapy in breast cancer. Biomed Pharmacother 2003 ; 57 : 463-70.
26. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer : a systematic review of the litetature and meta-analysis. Cancer Res 2004 ; 64 : 2941-55.
27. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003 ; 30 (5Suppl. 16) : 117-24.
28. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 ; 23 : 792-9.
29. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo : angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997 ; 151 : 1523-30.
30. Milano G. Pharmacological skills for targeting EGFR and VEGF. Bull Cancer 2005 ; 92 (Spec no) : S17-20.